Evidence map›Paper›PMID 40565058›Full record

ArticleInternational journal of molecular sciences2025

Overexpression of

Hanne Due, Asta Brogaard, Issa Ismail Issa, Maja Zimmer Jakobsen, Cathrine Sylvester, Anne Krogh Nøhr, Louiza Bohn Thomsen, Martin Kristian Thomsen, Rasmus Froberg Brøndum, Karen Dybkær

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hanne DueDepartment of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, 9000 Aalborg, Denmark.ORCID 0000-0003-0567-9967
Asta BrogaardDepartment of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, 9000 Aalborg, Denmark.ORCID 0009-0009-4915-1970
Issa Ismail IssaDepartment of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, 9000 Aalborg, Denmark.ORCID 0000-0002-0004-3030
Maja Zimmer JakobsenDepartment of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, 9000 Aalborg, Denmark.ORCID 0009-0009-2351-5676
Cathrine SylvesterDepartment of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, 9000 Aalborg, Denmark.ORCID 0009-0002-5277-9434
Anne Krogh NøhrCenter for Clinical Data Science, Aalborg University Hospital, and Aalborg University, 9260 Gistrup, Denmark.
Louiza Bohn ThomsenDepartment of Health Science and Technology, Aalborg University, 9260 Gistrup, Denmark.
Martin Kristian ThomsenDepartment of Biomedicine, Aarhus University, 8000 Aarhus, Denmark.ORCID 0000-0002-5055-7531
Rasmus Froberg BrøndumCenter for Clinical Data Science, Aalborg University Hospital, and Aalborg University, 9260 Gistrup, Denmark.ORCID 0000-0001-5537-6767
Karen DybkærDepartment of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, 9000 Aalborg, Denmark.ORCID 0000-0003-2488-435X

Funding

A.P Moeller Foundation NADanish Cancer Society R269-A15841
6 · The paper itself

Abstract

Numerous clinical trials have attempted to improve first-line R-CHOP treatment of diffuse large B-cell lymphoma (DLBCL) through the addition or substitution of drugs. The REMoDL-B trial, testing the addition of bortezomib (RB-CHOP), revealed that ABC and molecular high-grade DLBCL patients benefit from bortezomib. The aim of this study was to achieve a better understanding of the bortezomib response in DLBCL through a functional investigation of clinically identified markers. A retrospective analysis of transcriptional and clinical data from the REMoDL-B trial was conducted to identify genes associated with bortezomib response, identifying

Indexed as

BortezomibCell Cycle ProteinsLymphoma, Large B-Cell, DiffuseNuclear ProteinsAnimalsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorCell ProliferationCyclophosphamideDoxorubicinDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticHumansMaleAntineoplastic AgentsBortezomibCell Cycle ProteinsCyclophosphamideDoxorubicinNuclear ProteinsPrednisoneR-CHOP protocolRituximabVincristinebortezomibCDCA2CRISPRdiffuse large B-cell lymphomaDLBCLRB-CHOPtreatment response

Identifiers

PMID40565058
PMCPMC12193023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.